Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
The Company held the 12th meeting of the 8th Board of Directors on July 26, 2023, where it reviewed and approved the proposal on the appointment of a sponsor securities firm, agreeing to appoint Pacific Securities Co., Ltd. (hereinafter referred to as "Pacific Securities") as the Company's sponsor securities firm. The specific circumstances are announced as follows: